News

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

Cologne, Germany, November 19, 2026 – DISCO Pharmaceuticals (“DISCO”) today announced a strategic collaboration and option- to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need. Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is...

read more

Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data supporting an attractive therapeutic window for...

read more

Topadur’s Phase 2a Trial of TOP-N53 for Systemic Sclerosis-Associated Digital Ulcers Advances to Next Dose Levels

Schlieren-Zurich, Switzerland, 05 November 2026 – Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels. The trial is evaluating lead candidate TOP-N53 for the treatment of systemic sclerosis-associated digital ulcers....

read more

Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold presentations on its lead Radio-DARPin candidate MP0712, co-developed with...

read more